Updated:
Addex Therapeutics
Addex Therapeutics is a Swiss CNS biotech developing allosteric modulators for Parkinson's, epilepsy, and anxiety, led by CEO Tim Dyer since 2010.
Addex Therapeutics
Addex Therapeutics was founded in 2007 as a spin-out from the University of Geneva, led by CEO Tim Dyer since 2010. The company builds its pipeline on an allosteric modulation platform that engages drug targets at sites distinct from the orthosteric binding pocket, aiming for improved selectivity and safety. Wealth origin is not disclosed; Addex is a publicly traded entity on the Swiss exchange, with no family-office wealth backing. Addex's strategy centers on CNS disorders with high unmet need, including dyskinesia in Parkinson's disease (ADX-48621), genetic epilepsy (ADX-71373), and anxiety (ADX-10746). The company employs a hybrid model: in-house development and out-licensing deals with larger pharma. In 2022, it signed a CHF 20 million collaboration with Novartis to co-develop an mGluR5 program (per Novartis, 2022). Additional confirmed partners include Indivior for addiction therapies and Merck for adjacent modulation technology. Geographic footprint is primarily Swiss and European. As of May 2024, Addex employed roughly 25 professionals at its Geneva headquarters. It maintains a research platform it calls the "Addex Platform," which it licenses to select partners. The company is listed on the Swiss Exchange (SIX: ADXN) and has completed several financing rounds, including a CHF 12 million private placement in 2023 (per the firm's annual report, 2023). Adjacent structures include an academic collaboration network with Karolinska Institutet and University College London. Addex's structural differentiator is its exclusive focus on allosteric modulators — a niche that avoids the high failure rates of orthosteric binding drugs in CNS. This positions it as a platform-driven, not indication-driven, biotech: the value stems from the technology rather than any single pipeline asset. Governance follows a standard Swiss PLC model with a board led by Robert Lütjens, and no family-office control or concentrated ownership beyond public shareholders.
General information
Firm type
other
Year founded
2007
AUM
Undisclosed
Location
Region
Europe
Country
Switzerland
City
Geneva
Corporate office
Chemin des Mines 9, Geneva, Switzerland
Principals
Tim Dyer
Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Addex Therapeutics?
CEO Tim Dyer leads executive decisions since 2010, with oversight from a board chaired by Robert Lütjens. The company's pipeline and partnership strategy are guided by Chief Scientific Officer Vincent Mutel and a team of CNS drug discovery specialists (per the firm's corporate presentation, 2024).
How does Addex source proprietary deal flow?
Addex relies on its patented allosteric modulator platform to attract pharma partners. Deals emerge from out-licensing programs to larger firms like Novartis and Indivior, not through deal-flow origination typical of family offices. Academic collaborations with Karolinska Institutet and UCL also generate early-stage targets (per Addex corporate overview, 2024).
Is Addex structured as a family office or venture firm?
Neither. Addex Therapeutics is a publicly traded specialty biotech on the Swiss Exchange (SIX: ADXN). It is not a family office, asset manager, or investment vehicle. Its capital comes from equity issuances, private placements, and licensing fees, not from a single family's wealth (per the firm's 2023 annual report).
Does Addex participate in fund commitments or only direct deals?
Addex does not make external investments or fund commitments. Its business is drug development: it conducts clinical trials, out-licenses programs, and raises capital for internal R&D. The company's only deployment is into its own pipeline and platform technology (per the firm's business description).
What investment stages does Addex typically target?
Addex operates at the preclinical through Phase 2 clinical stage for CNS drugs. It does not invest in external assets; rather, it sells or in-licenses programs at various development stages. Its recent Phase 2a data for ADX-48621 exemplifies its stage focus (per May 2024 press release).
Which sectors does Addex explicitly avoid?
Addex focuses exclusively on CNS disorders and does not pursue oncology, metabolic diseases, or anti-infectives. Its allosteric platform is specific to GPCR targets relevant to neurology and psychiatry, per its published pipeline (per Addex corporate fact sheet, 2024).
How is Addex related to parent or related vehicles?
Addex has no parent company or holding structure. It is a standalone publicly traded firm with no ties to Novo Holdings, the Wellcome Trust, or other investors beyond their role as shareholders. It was spun out from the University of Geneva in 2007 but maintains no current academic parent (per the firm's history page).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: